Message from the Guest Editor

Dear Colleagues,

The paradoxical combination of an age-related increase in cancer incidence and a demographic shift towards senescent populations has greatly exacerbated the role of cancer as a major medical challenge of global proportions, creating an urgent need for the discovery of novel molecular cancer therapeutics. Seminal research has provided cumulative evidence that oncogene-driven tumorigenesis dictates the dysregulated occurrence of genotoxic, mitotic, metabolic, proteotoxic, immunomodulatory, and redox stress responses. On the other hand, tumorigenic progression depends on the counter-regulatory activation of cytoprotective stress response pathways that represent a specific mechanistic vulnerability amenable to therapeutic intervention by molecularly targeted therapeutics. This special issue gathers original research and review papers positioned at the forefront of our current understanding of molecular stress response dysregulation in cancer, representing both a major pathological driving force and promising therapeutic target.

Dr. Georg T. Wondrak
Guest Editor
Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 5.87, which equals rank 26/321 (Q1) in ‘Oncology’ and rank 24/191 (Q1) in ‘Cancer Research’.

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI